A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
This study is to assess the safety of a potential new drug DU-176b for the prevention of
 stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation
 (AF). The duration is 3 months of treatment and a 30 day follow-up visit.
Inclusion Criteria:

 1. Male or female, 18 to 80 years old.

 2. Able to provide written informed consent.

 3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)

 4. A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke
 (CHADS2) index score of at least 2

 Exclusion Criteria:

 1. Subjects with mitral valve disease or previous valvular heart surgery

 2. Known contraindication to any anticoagulant including vitamin K antagonists such as
 warfarin

 3. Known or suspected hereditary or acquired bleeding or coagulation disorder